FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced [electronic resource]
- Biomolecules 10 2019
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
2218-273X
10.3390/biom9110668 doi
Carcinoma, Non-Small-Cell Lung--blood Drug Approval ErbB Receptors--antagonists & inhibitors Europe Humans Lung Neoplasms--blood Mutation Protein Kinase Inhibitors--adverse effects Safety United States United States Food and Drug Administration--legislation & jurisprudence